Definiens Forms Strategic Partnership with Tessella
News Jan 16, 2009
Definiens has formed a systems integration partnership with Tessella, the information technology and consulting services company selected by R&D, science and engineering leaders for business-critical assignments.
Under the terms of the agreement, Definiens will train Tessella consultants to deploy and integrate Definiens image analysis technology into the IT infrastructures of large pharmaceutical and biotechnology companies.
Definiens’ image analysis software is built on the company’s proprietary Definiens Cognition Network Technology®, which emulates human cognitive processes to extract intelligence from images.
Tessella’s consultants will receive advanced training in Definiens XD, the company’s new platform for multidimensional image analysis. Tessella’s experts will develop new rule sets and applications for the seamless integration of Definiens technology across their clients’ IT infrastructure, and will provide on-site support and troubleshooting services. Tessella will also independently market software incorporating Definiens technology.
“Tessella aims to provide the best solution to our clients’ complex problems,” said Lawrence Hopkins, Associate Director at Tessella. “Definiens is clearly leading the image analysis field and we are delighted to be able to bring our clients two “best of breeds” in one solution – Definiens’ leading edge, innovative image analysis software and Tessella’s understanding of the underlying science being carried out by our clients and our excellent project delivery reputation.”
Tessella’s extensive network of consultants will accelerate the enterprise-wide integration of Definiens technology, as well as providing embedded support services to Definiens’ existing and future customers.
“Partnering with Tessella will enable our technology to be seamlessly implemented across large-scale enterprises,” said Manfred Voglmaier, Vice President of Business Development for Definiens’ Life Science division. “The partnership will expand our access to new markets and allow us to pursue larger clients for our premiere imaging analysis technology.”
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE